Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

176.95 +5.22 (+3.04%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
71 72 Next >
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
7 Dividend Stocks Worth Holding for the Long Haul
These dividend stocks are worth holding for the long term both for upside and income production that can add up quickly. 
Via InvestorPlace
2 Magnificent Dividend Growth Stocks to Load Up On Right Now
These two dividend-growth stocks are fantastic buys. 
Via The Motley Fool
Why AbbVie Stock Flew Higher on Monday
Investors and pundits alike continued to be impressed by the company's latest earnings report. 
Via The Motley Fool
Drug Maker AbbVie Stock Sees RS Rating Jump To 81
AbbVie stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 78 to 81. 
Via Investor's Business Daily
AbbVie Analysts Boost Their Forecasts Following Strong Earnings
AbbVie Inc (NYSE: ABBV) reported better-than-expected fourth-quarter earnings on Friday. 
Via Benzinga
AbbVie Earnings Preview
Via Benzinga
This Is What Whales Are Betting On AbbVie
Via Benzinga
Better Dividend Stock: Pfizer vs. AbbVie
Both offer above-average yields but which can deliver the most dividend income over the long run? 
Via The Motley Fool
Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
3 Fabulous Dividend Stocks to Buy in February
These stocks offer great dividends and more. 
Via The Motley Fool
7 Dividend Stocks That Pay Me More Than $500 Per Month
These stocks pay safe, reliable, and growing dividends. 
Via The Motley Fool
AbbVie (ABBV) Q4 2023 Earnings Call Transcript
ABBV earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products. 
Via Benzinga
AbbVie turns a corner; patent cliff fears were overblown
AbbVie's patent cliff is already a thing of the past with Skyrizi and Rinvoq outperforming and other assets also strong. Dividends are safe, growth is back. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
AbbVie Expects Two Of Its Biggest Drugs To Bring In $27 Billion In 2027. And Neither One Is Humira.
The company raised its long-term guidance for four products on Friday. Two will top $27 billion in 2027 sales, the company says. 
Via Investor's Business Daily
AbbVie Posts Less-Than-Healthy Financial Results For 2023
Pharmaceuticals company AbbVie reported its Q4 and full year financial results for 2023. 
Via Talk Markets
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. 
Via Benzinga
Earnings Scheduled For February 2, 2024
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion. 
Via Benzinga
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024
Biotech stocks are warming up in January and look to continue upward in 2024 as the economy improves. Here are three to check out. 
Via InvestorPlace
Topics Economy
Exposures Economy
Best Income Stocks 2024
The pros and cons of 7 companies in 4 different sectors. 
Via Talk Markets
Goldman Sachs, AbbVie And A Major Chipmaker: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Steve Weiss of Short Hills Capital Partners said Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) 
Via Benzinga
3 Stocks Enjoying Favorable Analyst Coverage
We see daily analyst upgrades and downgrades, coming with price targets. They can be helpful tools for investors, providing a more structured plan and helping to inject positivity surrounding future... 
Via Talk Markets
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
Via Get News
Exposures Product Safety
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
--News Direct-- 
Via News Direct
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.